<?xml version="1.0" encoding="UTF-8" ?><!-- Generated on Tue, 30 Jun 2026 21:54:16 -0400--><rss version="2.0">
    <channel>
        <title>DiaMedica Therapeutics, Inc. (DMAC) Press Releases</title>
        <link>https://www.diamedica.com/investors/press-releases/rss</link>
        <description></description>
        <language>en-us</language>
                                            <image>
                <url>https://d1io3yog0oux5.cloudfront.net/diamedica/files/theme/images/logo-sm.png</url>
                <title>DiaMedica Therapeutics, Inc. Logo</title>
                <link>/investors</link>
            </image>
                <generator>Equisolve Investor Relations Suite</generator>
        
                            <item>
                <title><![CDATA[DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1730/diamedica-therapeutics-announces-first-patients-dosed-in</link>
                <pubDate>Tue, 23 Jun 26 08:30:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1730/diamedica-therapeutics-announces-first-patients-dosed-in</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Receives FDA Feedback on DM199 Preeclampsia Nonclinical Program]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1729/diamedica-receives-fda-feedback-on-dm199-preeclampsia</link>
                <pubDate>Tue, 16 Jun 26 08:30:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1729/diamedica-receives-fda-feedback-on-dm199-preeclampsia</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics to Present at the Jefferies Global Healthcare Conference 2026]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1728/diamedica-therapeutics-to-present-at-the-jefferies-global</link>
                <pubDate>Wed, 27 May 26 16:30:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1728/diamedica-therapeutics-to-present-at-the-jefferies-global</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics Announces 75% Enrollment Milestone in ReMEDy2 Phase 2/3 Acute Ischemic Stroke Trial]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1727/diamedica-therapeutics-announces-75-enrollment-milestone</link>
                <pubDate>Wed, 20 May 26 08:30:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1727/diamedica-therapeutics-announces-75-enrollment-milestone</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics to Participate in the 2026 RBC Capital Markets Global Healthcare Conference]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1726/diamedica-therapeutics-to-participate-in-the-2026-rbc</link>
                <pubDate>Tue, 12 May 26 16:15:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1726/diamedica-therapeutics-to-participate-in-the-2026-rbc</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Highlights]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1725/diamedica-therapeutics-reports-first-quarter-2026-financial</link>
                <pubDate>Wed, 06 May 26 16:30:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1725/diamedica-therapeutics-reports-first-quarter-2026-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics to Report First Quarter 2026 Financial Results and Provide a Business Update May 7, 2026]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1724/diamedica-therapeutics-to-report-first-quarter-2026</link>
                <pubDate>Thu, 30 Apr 26 08:25:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1724/diamedica-therapeutics-to-report-first-quarter-2026</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics Reports Full Year 2025 Financial Results and Provides Business Highlights]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1723/diamedica-therapeutics-reports-full-year-2025-financial</link>
                <pubDate>Mon, 30 Mar 26 16:45:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1723/diamedica-therapeutics-reports-full-year-2025-financial</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics to Report Fourth Quarter 2025 Financial Results and Provide a Business Update March 31, 2026]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1722/diamedica-therapeutics-to-report-fourth-quarter-2025</link>
                <pubDate>Mon, 23 Mar 26 08:25:00 -0400</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1722/diamedica-therapeutics-to-report-fourth-quarter-2025</guid>
                                                                            </item>
                    <item>
                <title><![CDATA[DiaMedica Therapeutics Receives Health Canada Clearance to Initiate Phase 2 Study of DM199 in Preeclampsia]]></title>
                <description><![CDATA[]]></description>
                <link>https://www.diamedica.com/investors/press-releases/detail/1721/diamedica-therapeutics-receives-health-canada-clearance-to</link>
                <pubDate>Thu, 05 Mar 26 07:35:00 -0500</pubDate>
                <guid isPermalink="true">https://www.diamedica.com/investors/press-releases/detail/1721/diamedica-therapeutics-receives-health-canada-clearance-to</guid>
                                                                            </item>
            </channel>
</rss>